Keep up to date with the latest developments at CDISC and follow our news feeds!
Austin, TX – 10 January 2023 – CDISC today announced three members have joined its Board of Directors: Jonathan Chainey, Dominic Labriola and Rhona O’Donnell each began serving a three-year term at the beginning of the year. Existing Member, Dr. Erik Pulkstenis, now leads the Board as Chair.
AUSTIN, TX and PLEASANTON, CA — Dec. 14, 2022 — Veeva Systems (NYSE: VEEV) and CDISC are pleased to announce that Dan Crawford, Veeva Clinical Database (CDB) principal consultant, has been elected chair of the CDISC Advisory Council (CAC) . The CAC comprises representatives from CDISC platinum members who play an important role in shaping CDISC’s development and direction, providing the CDISC executive team with recommendations that support CDISC goals.

CDISC invites you to an FDA-hosted public broadcast during the SEND Team’s fall virtual meetings. The broadcast is an opportunity for stakeholders to stay informed on what’s going on with the development of SEND and its use in regulatory submissions, as well as hear use cases from our global SEND user community.

METUCHEN, NJ and AUSTIN, TX – 24 May 2022 – Embleema Inc. and CDISC have announced a collaboration to develop new standards for experimental assays and bioinformatics protocols to facilitate monitoring the activity of Cell and Gene Therapy Products (CGTP).
Austin, TX – 27 Apr 2022 – CDISC today announced an expansion of its offerings with the official affiliation of volunteer-based Trial Master File (TMF) Reference Model Group. The combined organizations will operate under the CDISC brand and continue serving the clinical research community by providing resources that foster greater efficiencies across the industry ecosystem.